---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-014660"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T08:54:41.867202+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics reports 2022 net loss of $38.9M; NAVIGATE trial on track

## Summary
- Net loss $38.9M ($0.65/share) vs $30.7M ($0.52) in 2021.
- R&D expenses $31.7M, up from $23.8M, driven by NAVIGATE trial costs.
- Cash $18.6M; $50M credit line available; expects funding through Dec 2024.
- NAVIGATE trial randomized 357 patients; DSMB positive; interim results Q4 2024.
- Evaluating Phase 2 trial of belapectin + Keytruda for head and neck cancers.

## SEC filing metadata
- accession: 0001140361-23-014660
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036123014660/0001140361-23-014660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036123014660/brhc10050428_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-014660
- JSON: https://secwatch.observer/filing/0001140361-23-014660.json
- Plain text: https://secwatch.observer/filing/0001140361-23-014660.txt

## Key facts
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported the year ended December 31, 2022 results: net income $38.9 million, EPS ($0.65) per share.
  - Period: the year ended December 31, 2022
  - Net income: $38.9 million
  - EPS: ($0.65) per share
  - Result: reported results
  source text: For the year ended December 31, 2022, the Company reported a net loss applicable to common stockholders of $38.9 million, or ($0.65) per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036123014660/0001140361-23-014660-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.